Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%

Sezer, A.Gogishvili, M.Bentsion, D.Kilickap, S.Lowczak, A.Gumus, M.Gladkow, O.Clingan, P.Sriuranpong, V.Rizvi, N.Lee, S.Li, S.Snodgrass, P.Navarro, M.Lowy, I.Rietschel, P.2020-10-202020-10-2020191556-0864http://hdl.handle.net/11727/4938enginfo:eu-repo/semantics/openAccessnon-small-cell lung canceranti-PD-1cemiplimabCemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%Conference Object1410S638S638000492162203260